Asia Pacific Vagus Nerve Stimulation Market
市场规模（十亿美元）
CAGR :
% 
USD
245.79 Million
USD
701.13 Million
2025
2033
 Forecast Period |
2026 –2033 |
 Market Size (Base Year) |
USD 245.79 Million |
 Market Size (Forecast Year) |
USD 701.13 Million |
 CAGR |
% |
| Major Markets Players |
|
亚太Vagus Nerve刺激市场,按产品类型(可种植VNS设备和外部VNS设备)、生物材料(陶瓷、金属和多聚体)、应用(Pain管理、癫痫缉获、肥胖管理、抑郁和焦虑等)、病人类型(Adults、小儿科和老年科)、最终用户(医院、门诊外科中心、专科中心等)、分销渠道(Direct Tender、零售销售等) -- -- 2033年行业趋势和预测
亚太真空神经刺激市场概况
亚太活泼神经刺激市场的价值2025年2.4579亿美元预计将达到截至2033年的7.013亿美元,生长在一个从2026年到2033年CAGR为14.00%.受癫痫和抗治疗抑郁等神经系统疾病日益普遍、对神经调节疗法的认识不断提高以及本区域新兴经济体的保健投资不断增加等驱动,市场正在稳步扩大。 在中国、日本、印度和韩国等国家扩大先进神经刺激装置的获取范围,进一步支持市场采用。
慢性神经和精神疾病的负担日益加重,加上传统药物疗法的局限性,正在鼓励保健提供者将活泼神经刺激作为一种有效的辅助或替代治疗选择。 植入式和非侵入式VNS装置的持续发展,以及亚太市场的临床研究活动和监管审批不断增长,正在进一步加快采用。 此外,保健基础设施的不断发展以及专业神经护理中心的扩大正在加强区域市场前景。
主要市场趋势和见解
- 中国主导了亚太多变神经刺激市场,2025年收入份额最大,为34.62%,辅以神经功能失调的沉重负担,先进医院基础设施迅速扩大,一级医疗中心越来越多地采用神经调节疗法。
- 由耐药性癫痫和长期神经紊乱症的强临床疗效所驱动,可植入的VNS设备段在2025年以63.27%的比重带动了市场.
- 预计从2026年到2033年,印度将是增长最快的国家,预计CAGR为8.1%,而神经系统疾病发病率上升、获得专业神经护理的机会增加、对先进的非药物治疗方案的认识提高等都为印度提供了燃料。
- 外部 VNS 数据 设备是增长最快的产品类型,预计将登记8.4%的CAGR,反映出对非侵入性和患者友好性神经调节疗法的需求激增。
- 2025年,金属部分在生物材料类别中占据了主导地位,收入份额为52.18%,其主导地位是其耐久性高、生物相容性高以及支持长期植入稳定性的能力。
- 由于中国、日本和印度等主要国家的抗药性癫痫发病率高,兴奋剂缉获量占市场的46.85%。
- 抑郁症和焦虑症是增长最快的应用类别,CAGR为8.3%,其驱动力在于心理健康负担不断加重和越来越多地采用神经调节疗法。
市场大小和预测
- 全球市场价值(2025):245.79万美元
- 预期市场价值(2033):70,113万美元
- CAGR预测(2026-2033):14.00%
- 2025年领先国家:中国
- 最快增长的国家:印度
报告范围和范围亚太真空神经刺激市场分割
|
属性 |
亚太真空神经刺激键市场透视 |
|
覆盖部分 |
|
|
涵盖国家 |
亚太 中国 * 日本 • 印度 韩国 新加坡 马来西亚 澳大利亚 泰国 印度尼西亚 菲律宾 亚太其他地区 |
|
关键市场玩家 |
• 妇女利瓦诺瓦PLC(吴. • 妇女电子Core股份有限公司(美国). • 妇女MicroTransponder Inc. 互联网档案馆的存檔,存档日期2013-12-02.(美国). • 妇女美敦诺尼(爱尔兰) • 妇女亚伯特(美国). · 波士顿科学公司(美国) • Neuropace公司(美国) tVNS技术股份有限公司(德国) • Parasym有限公司(英国) Setpoint医疗公司(美国) · Neurosigma公司(美国) • 突发生物医学公司(美国) · 神经软体(俄罗斯) · NeuroMetrix公司(美国) 卡拉卫生(美国) • 神经一号医疗技术公司(美国) · NIHON KOHDEN公司(日本) Omron保健有限公司(日本) · Cyberonics(美国) 高级神经调节系统(美国) |
|
市场机会 |
在门诊和家庭护理场所越来越多地采用非侵入性VNS装置 将临床症状扩大到癫痫和抑郁症之外 · 加强AI驱动的刺激参数优化的整合,以便实现个性化神经疗法 |
|
添加数据信息集的值 |
除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。 |
亚太真空神经刺激市场趋势
趋势:扩大治疗神经疾病中的神经调节
整个亚太区域的保健提供者越来越多地对抗药性癫痫和抑郁症患者采用反复无常的神经刺激,因为常规药理疗法往往显示长期疗效有限。 先进的可植入性和非侵入性刺激系统的结合,正在通过定向神经调节和个性化治疗环境来改善临床结果. 神经学中心和专科医院也在利用数字监测工具跟踪患者的反应并随着时间的推移优化刺激参数,而不断增长的临床研究活动正在扩大治疗理解. 例如,日本和中国的医院正在对癫痫患者进行长期的VNS结果研究,以完善治疗规程。
亚太真空神经刺激市场动态
主要市场驱动力:对高级神经治疗替代品的需求增加
癫痫、抑郁症和其他神经系统紊乱症的日益普遍,正在驱使人们要求用活泼的神经刺激作为在常规药物疗法无法产生持续结果时的有效替代品。 在中国、日本和印度等国家,扩大保健基础设施和增加获得专门神经护理的机会,正在加速采用可植入和非侵入装置。 医疗器械制造商还注重改善器械安全,电池使用寿命,并刺激精度来增强临床接受能力. 例如,印度正在目睹三级医院对抗药性癫痫病例越来越多地采用VNS疗法。
关键限制/挑战:高处理和装置成本限制
亚太挥发性神经刺激市场的一个主要挑战是可植入装置、外科手术程序和长期治疗管理成本高,限制了价格敏感的保健系统的可获性。 一些国家的报销范围有限,进一步限制了病人的收养,特别是在自付保健开支仍然很高的发展中经济体。 此外,对专业外科专门知识和植入后监测的需求增加了总体治疗负担。 例如,由于保险范围有限,程序费用高,东南亚的病人往往难以获得VNS治疗。
主要市场机会:非侵入性和个性化神经刺激解决方案的增长
非侵入性活性神经刺激装置的日益发展为市场扩张提供了极好的机会,特别是在对低风险疗法的需求正在增加的门诊和家庭护理环境中。 在数字健康一体化和AI驱动的刺激控制方面取得的进展,使得根据病人反应数据调整治疗的个性化治疗方法成为可能. 预计这一转变将改善获得服务的机会并减少对外科手术的依赖,特别是在新兴的保健市场。 例如,韩国和中国正在探索与移动健康平台相结合的可穿戴VNS设备,用于个性化治疗管理。
亚太真空神经刺激市场范围
根据产品类型、生物材料、应用、病人类型、最终用户和分销渠道,对亚太活泼神经刺激市场进行分化。
- 按产品类型
根据产品类型,亚太活性神经刺激市场被分入可植入的VNS装置和外部VNS装置. 由于抗药性癫痫和长期神经紊乱症的临床疗效很强,可植入的VNS装置部分在2025年占了63.27%的市场份额。 这些装置因其持续的治疗结果和既定的监管批准,被医院和专科神经科中心广泛采用. 中国和日本等国家增加外科专业技术,扩大神经调节基础设施,进一步支持收养. 它们提供持续的刺激,提高慢性病患者的反应率. 然而,高昂的程序费用和手术要求限制了价格敏感的市场的无障碍性。 尽管存在挑战,但可植入的系统在严重情况下仍然是临床金本位。
外部VNS设备部分预计将在2026年至2033年的CAGR增长最快,为8.4%,原因是对非侵入性和患者友好性神经调节疗法的需求不断增加。 这些装置消除了手术植入的需要,使其适合门诊和家庭护理环境。 提高对早期神经紊乱症管理的认识进一步支持收养。 可穿戴刺激系统的技术进步正在改善舒适性、可携带性和处理精度。 在抑郁症,焦虑症和偏头痛管理中扩大使用也正在加速增长. 越来越倾向于成本效益高的治疗办法,正在加强新兴经济体的渗透。
- 生物物质
在生物材料的基础上,亚太活泼神经刺激市场被分入陶瓷、金属和聚合材料。 金属生物质部分在2025年占了52.18%的市场份额,其驱动力在于其耐久性高、生物相容性高以及支持长期植入稳定性的能力。 钛等金属因其强度和抗腐蚀性而被广泛用于可植入的脉冲发电机和电极组件. 这些材料确保在神经学应用中可靠的信号传输和装置寿命. 在日本和中国各地的医院植入程序中大力采用,进一步强化了支配地位。 小型化的持续进步正在提高设备效率。 然而,与费用和手术复杂性有关的关切仍然是限制因素。
Polymeric Biomatics分部预计将在2026年至2033年8.0%的CAGR中出现最快的增长,其动力是灵活、轻量级和最低侵入性设备设计的使用量不断增加。 在可穿戴的和外部的VNS系统中,多聚体可以改善病人的舒适性和适应性。 它们的多能性支持下一代神经刺激装置的创新. 对非侵入性疗法的日益重视正在大大地刺激对聚合物成分的需求。 扩大生物相容和生物相容材料的研发工作正在进一步加快采用。 该部分还受益于具有成本效益的制造业和可扩展性优势。
- 通过应用程序
根据应用情况,亚太活泼神经刺激市场分为疼痛管理、癫痫发作、肥胖管理、抑郁和焦虑等。 2025年,由于中国、日本和印度等主要国家的抗药性癫痫发病率高,兴奋剂缉获量占了市场的46.85%。 当抗癫痫药物未能有效控制缉获量时,VNS疗法被广泛用作辅助治疗. 支持长期减少缉获的强有力的临床证据正在加强神经学中心的采用。 提高诊断率和改善获得先进治疗的机会,进一步支持了增长。 医院继续倾向于对严重和慢性癫痫患者进行VNS治疗。 该部分受益于发达保健系统的有力偿还支助。
2026年至2033年,由于心理健康负担不断加重和越来越多地采用以神经调节为基础的疗法,CAGR增长最快,为8.3%。 作为抗治疗性抑郁症的非药物治疗选择,VNS正在获得牵引力。 亚太区域各国对心理健康状况的认识日益提高并减少了耻辱感,这正在促进患者的吸收。 扩大临床试验正在验证其在精神应用方面的功效。 加强与数字心理健康平台的融合,进一步加快采用. 对个性化神经疗法的需求也日益增加,也为这一段提供了支持。
- 按患者类型
根据患者类型,亚太活体神经刺激市场分为成人、儿科和老年病。 成人病人部分在2025年占了71.34%的市场份额,主要原因是在工作年龄人群中癫痫、抑郁和慢性神经紊乱发病率高。 成人是可植入的VNS程序的主要候选者,因为更适合外科手术和长期治疗。 与精神压力有关的精神疾病不断增加,进一步推动了这一群体的需求。 大力提供医院神经科护理,有助于采用更高的治疗方法。 持续的临床监测也提高了成人的治疗效力. 该部分受益于发达市场范围更广的保险。
预计儿科病人部分在2026至2033年的CAGR增长最快,为7.9%,原因是对儿童癫痫的诊断增加,儿童对神经调节疗法的接受程度提高。 在药物失效的复发性癫痫病例中越来越多地使用VNS。 设备小型化方面的进步正在改善年轻病人的安全和适宜性。 父母和儿科神经科医生的认识不断提高,支持早期干预。 扩大儿科用药临床指导,进一步加快收治. 该部门还受益于各大医院的专业儿科神经学方案。
- 按终端用户
在最终用户的基础上,亚太活泼神经刺激市场分为医院、流动外科中心、专科中心等。 2025年,由于有先进的神经科和熟练的外科专业人员,医院部分占了市场的58.39%。 由于需要进行外科手术和手术后监测,医院仍然是可移植VNS程序的主要场所。 增加中国、日本和印度对神经护理基础设施的投资正在加强支配地位。 医院还受益于综合诊断和治疗能力。 为癫痫和抑郁症管理而强劲的患者流入进一步支持了生长. 政府扩大保健倡议加强了这一部分。
预计专科中心部分在2026年至2033年的CAGR增长最快,为8.2%,其动力是日益重视专门的神经学和精神保健设施。 这些中心提供具有专门知识和个性化治疗计划的高级神经刺激疗法。 对门诊和长期神经调节护理日益增长的需求正在推动收养。 心理健康意识的提高也支持扩大精神病专科诊所。 与设备制造商加强临床研究合作,正在进一步加快增长。 该部分正在受益于更快的治疗和减轻的医院负担。
- 按发行频道
以分销渠道为基础,亚太活泼神经刺激市场被分入了直接招标,零售等行业. 直接招标部分在2025年占了66.21%的市场份额,由医院、政府保健系统和专科神经科中心的大规模采购所驱动。 通常通过机构合同购买可植入的VNS设备,因为这些设备成本高,手术性质高. 中国和印度等国的公共卫生方案大力参与支持这一渠道。 制造商倾向于直接销售长期服务协议和维修合同。 大量购买可确保保健提供者的成本效益。 该部分受益于医院网络中结构化的采购系统。
零售销售部分预计将在2026年至2033年的CAGR增长最快,为8.1%,由外部VNS装置和可穿戴神经调制产品的不断增多所驱动. 提高消费者对非侵入性疗法的认识有助于患者直接购买。 数字保健平台和电子药用渠道的扩大正在进一步加快采用。 越来越多的人倾向于家庭治疗办法,这增加了需求。 便携式设备的技术进步正在改善无障碍环境。 整个城市人口的心理健康自我护理趋势不断上升,也使这部分人受益。
亚太真空神经刺激市场区域分析
中国主导了亚太多变神经刺激市场,2025年收入份额最大,为34.62%,辅以神经功能失调的沉重负担,先进医院基础设施迅速扩大,一级医疗中心越来越多地采用神经调节疗法。 该国受益于对医疗技术的大力投资、越来越多的临床研究活动以及越来越多的可植入的抗治疗性癫痫和抑郁的VNS装置。 扩大获得专门神经护理的机会并提高对非药物治疗选择的认识,进一步推动了市场的增长。 此外,政府注重医疗现代化和医院系统中先进神经刺激技术的日益融合,继续强化了中国在地区市场上的领先地位。
印度真空神经刺激市场透视
由于癫痫、抑郁症和其他神经系统疾病日益普遍,印度的神经刺激市场正在快速增长,同时获得特殊神经护理的机会也有所增加。 在一级和二级城市,扩大医院基础设施和越来越多地采用先进的神经刺激疗法正在支持市场渗透。 人们对抗治疗性癫痫管理的认识日益提高,并逐步采用非侵入性VNS装置,这进一步推动了需求。 此外,增加保健支出和增加临床神经学专门知识正在加强长期市场增长前景。
日本真空神经刺激市场透视
由于大力采用先进的神经调节技术和高度发达的神经学保健系统,日本活泼神经刺激市场正在稳步增长。 医院和专科中心大力开展临床研究并采用早期技术,支持越来越多地使用VNS疗法治疗癫痫和抑郁症。 该国注重精密医学和数字健康监测系统的一体化,正在提高治疗效率。 此外,越来越偏好最低侵入性神经疗法,继续有助于扩大市场。
中国真空神经刺激市场透视
中国活泼的神经刺激市场正在迅速发展,其驱动力是神经功能失调的沉重负担和整个城市和半城市地区扩大保健基础设施。 三级医院越来越多地采用可植入和非侵入性VNS装置,支持了强有力的市场渗透。 政府注重保健现代化和增加对神经学研究的投资,正在进一步加快增长。 此外,人们日益认识到癫痫和抑郁症的先进治疗选择,这加强了中国在亚太市场的领导地位。
韩国真空神经刺激市场透视
由于医疗器械创新能力强并越来越多地采用先进的神经调节疗法,韩国的活泼神经刺激市场正在稳步增长。 对抑郁和焦虑等心理健康障碍的日益重视正在推动对基于VNS的治疗的需求。 医院和专科诊所越来越多地将神经刺激技术纳入治疗途径。 此外,可穿戴和非侵入性VNS系统的进步正在支持市场扩张。
亚太真空神经刺激市场份额
亚太活泼神经刺激行业主要由有良好基础的公司领导,包括:
- Liva Nova PLC (英国).
- 电子Core股份有限公司(美国)
- MicroTransponder Inc.(美国)
- 梅德罗尼克(爱尔兰)
- 阿博特 (美国).
- 波士顿科学公司(美国)
- Neuropace公司(美国)
- tVNS技术股份有限公司(德国)
- Parasym有限公司 (英国)
- Setpoint医疗公司(美国)
- Neurosigma股份有限公司(美国)
- 突触生物医学公司(美国)
- 神经软体( 俄罗斯)
- NeuroMetrix股份有限公司(美国)
- 卡拉健康(美国)
- 神经一号医疗技术公司(美国)
- (日本)
- Omron保健有限公司(日本)
- Cyberonics (美国).
- 高级神经调节系统(U.S.
亚太真空神经刺激市场的最新动态
- 2025年2月,台湾国家健康保险扩大了利瓦诺瓦的Vagus Nerve刺激治疗系统的报销范围,改善了抗药性癫痫患者获得高级神经调节治疗的机会. 这项政策的更新预计将通过减少财政障碍和加强神经病学中心的临床吸收,大大加强医院采用可植入的VNS装置。 该决定反映出人们日益认识到VNS疗法是亚太保健系统内癫痫管理中的标准辅助治疗。
- 2025年2月,LivaNova为其VNS治疗系统发布了更新的安全性和有效性信息,加强了其在治疗不回应药物的癫痫患者方面的长期临床可靠性. 该更新强调了长期植入期间的持续治疗性能、设备耐久性以及持续的安全结果。 这些事态发展正在促使亚太医院,特别是日本和中国的高级神经护理中心增加收养人数。
- 2024年12月,LivaNova在美国癫痫学会年度会议上介绍了VNS治疗的最新临床数据,强调抗药性癫痫患者的缉获频率持续地长期降低. 调查结果虽然在全球范围提出,但与日本、中国和印度等亚太市场密切相关,因为这些国家的癫痫负担很大,采用神经调节疗法的情况也在增加。 这些结果进一步加强了医师对VNS疗法的信心,支持其扩大临床对神经学实践的整合.
- 2024年6月,一份在"Epilepsia Open"上发表的同行评审研究报告称,用Vagus Nerve刺激疗法治疗的日本患者的长期取药控制结果有所改善,表明抗药性癫痫病例在临床上有很大的好处. 研究突出了日本神经学中心内强有力的采用和结构化的后续系统,反映了该国先进的神经调节生态系统. 这些发现进一步支持了日本在亚太地区临床研究和VNS疗法实际应用方面的领导作用.
- 2023年3月,亚太地区的神经调节研究活动大幅增加,越来越注重利用先进的神经模型技术,了解癫痫和精神障碍中的Vagus Nerve刺激机制. 日本等国家的学术和临床研究机构为提高对VNS如何调节大脑网络和减少缉获活性的认识作出了贡献。 这些见解有助于优化刺激参数并加快开发本区域下一代个性化神经调节疗法。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC VAGUS NERVE STIMULATION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 LIFELINE CURVE , BY PRODUCT TYPE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 KEY STRATEGIC INITIATIVES
5 REGULATIONS OF ASIA PACIFIC VAGUS NERVE STIMULATION MARKET
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS
6.1.2 INNOVATIVE NON-INVASIVE VAGUS NERVE STIMULATION DEVICES INTRODUCED TO MEET DEMAND
6.1.3 RISE IN PRODUCT APPROVALS
6.1.4 PRODUCT DEVELOPMENT IN RECENT YEARS
6.2 RESTRAINTS
6.2.1 HIGH MAINTENANCE AND DEVICE COSTS TO RESTRAIN ADOPTION OF VAGUS NERVE STIMULATORS
6.2.2 RISE IN PRODUCT RECALL
6.2.3 UNFAVORABLE REIMBURSEMENT POLICIES
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.3.2 RISING GOVERNMENT INITIATIVES FOR NEUROLOGICAL DISEASE
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES
6.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS
6.4.3 STRINGENT REGULATIONS FOR APPROVAL OF MEDICAL DEVICES
7 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 IMPLANTABLE VNS DEVICE
7.3 EXTERNAL VNS DEVICE
8 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL
8.1 OVERVIEW
8.2 METALLIC
8.3 POLYMERIC
8.4 CERAMICS
9 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 EPILEPTIC SEIZURES
9.2.1 IMPLANTABLE VNS DEVICE
9.2.2 EXTERNAL VNS DEVICE
9.3 DEPRESSION AND ANXIETY
9.3.1 IMPLANTABLE VNS DEVICE
9.3.2 EXTERNAL VNS DEVICE
9.4 PAIN MANAGEMENT
9.4.1 IMPLANTABLE VNS DEVICE
9.4.2 EXTERNAL VNS DEVICE
9.5 OBESITY MANAGEMENT
9.5.1 IMPLANTABLE VNS DEVICE
9.5.2 EXTERNAL VNS DEVICE
9.6 OTHERS
10 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.2.1 IMPLANTABLE VNS DEVICES
10.2.2 EXTERNAL VNS DEVICES
10.3 GERIATRIC
10.3.1 IMPLANTABLE VNS DEVICES
10.3.2 EXTERNAL VNS DEVICES
10.4 PEDIATRIC
10.4.1 IMPLANTABLE VNS DEVICES
10.4.2 EXTERNAL VNS DEVICES
11 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY END USER
11.1 OVERVIEW
11.2 SPECIALTY CENTERS
11.3 HOSPITALS
11.4 AMBULATORY SURGICAL CENTERS (ASCS)
11.5 OTHERS
12 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 SOUTH KOREA
13.1.4 INDIA
13.1.5 AUSTRALIA
13.1.6 SINGAPORE
13.1.7 THAILAND
13.1.8 MALAYSIA
13.1.9 INDONESIA
13.1.10 PHILIPPINES
13.1.11 REST OF ASIA-PACIFIC
14 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ELECTROCORE, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 LIVANOVA PLC
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 MEDTRONIC
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 SETPOINT MEDICAL
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 TVNS TECHNOLOGIES GMBH
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NEUROPIX COMPANY LTD.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BRAIN CONTROL CO. LTD
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 CIRTEC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 MICROTRANSPONDER INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 PARASYM LTD
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 RESHAPE LIFESCIENCES INC. (2021)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 SOTERIX MEDICAL INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC IMPLANTABLE VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC EXTERNAL VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC METALLIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC POLYMERIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC CERAMICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC ADULTS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC GERIATRICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC SPECIALTY CENTERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC HOSPITALS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC AMBULATORY SURGICAL CENTERS (ASCS) IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC DIRECT TENDER IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC RETAIL SALES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 37 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 38 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 51 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 52 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 53 CHINA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 54 CHINA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 CHINA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 CHINA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 57 CHINA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 CHINA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 CHINA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 60 CHINA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 61 CHINA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 62 CHINA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 CHINA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 CHINA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 66 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 67 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 68 JAPAN VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 69 JAPAN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 JAPAN EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 JAPAN DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 JAPAN PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 JAPAN OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 JAPAN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 JAPAN ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 76 JAPAN GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 77 JAPAN PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 78 JAPAN VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 JAPAN VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 81 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 82 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 83 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 84 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 SOUTH KOREA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 SOUTH KOREA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 SOUTH KOREA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 SOUTH KOREA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 89 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 90 SOUTH KOREA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 91 SOUTH KOREA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 SOUTH KOREA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 96 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 97 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 98 INDIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 99 INDIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 100 INDIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 101 INDIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 102 INDIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 103 INDIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 104 INDIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 INDIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 106 INDIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 INDIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 108 INDIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 INDIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 111 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 112 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 113 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 114 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 115 AUSTRALIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 116 AUSTRALIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 AUSTRALIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 118 AUSTRALIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 119 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 AUSTRALIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 AUSTRALIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 122 AUSTRALIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 123 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 125 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 126 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 127 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 128 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 129 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 130 SINGAPORE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 131 SINGAPORE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 132 SINGAPORE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 133 SINGAPORE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 134 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 135 SINGAPORE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 136 SINGAPORE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 137 SINGAPORE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 140 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 141 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 142 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 143 THAILAND VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 144 THAILAND VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 145 THAILAND EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 THAILAND DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 147 THAILAND PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 148 THAILAND OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 149 THAILAND VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 150 THAILAND ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 151 THAILAND GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 152 THAILAND PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 153 THAILAND VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 154 THAILAND VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 155 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 156 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 157 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 158 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 159 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 160 MALAYSIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 161 MALAYSIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 162 MALAYSIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 163 MALAYSIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 164 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 165 MALAYSIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 166 MALAYSIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 MALAYSIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 168 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 169 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 170 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 171 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 172 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 173 INDONESIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 174 INDONESIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 175 INDONESIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 176 INDONESIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 177 INDONESIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 178 INDONESIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 179 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 180 INDONESIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 181 INDONESIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 182 INDONESIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 183 INDONESIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 184 INDONESIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 185 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 186 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 187 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 188 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 189 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 190 PHILIPPINES EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 191 PHILIPPINES DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 192 PHILIPPINES PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 193 PHILIPPINES OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 194 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 195 PHILIPPINES ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 196 PHILIPPINES GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 197 PHILIPPINES PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 198 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 199 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 200 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 201 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 202 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
图片列表
FIGURE 1 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR INNOVATIVE NON–INVASIVE VAGUS STIMULATION DEVICES AND THE INCREASED PREVALENCE OF NEUROLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE ASIA PACIFIC VAGUS NERVE STIMULATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMPLANTABLE VNS DEVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC VAGUS NERVE STIMULATION MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC VAGUS NERVE STIMULATION MARKET
FIGURE 14 INCIDENCE OF ADULT-ONSET BRAIN DISORDERS IN THE U.S. IN 2021
FIGURE 15 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2021
FIGURE 16 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 17 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 18 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2021
FIGURE 20 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2021
FIGURE 24 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2021
FIGURE 28 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, 2021
FIGURE 32 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 36 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 40 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 41 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 44 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
